Egalet

Værløse, Denmark Founded: 1995 • Age: 31 yrs
Therapeutics for pain management are developed with abuse-deterrent designs.
Annual revenue $2.0M Latest available
Total funding $70.9M 8 rounds
Employees 1 Tracked headcount
Investors 9 Known backers
Products 1 Services tracked
Competitors 11 Brand Intelligence

About Egalet

Egalet is a company based in Værløse (Denmark) founded in 1995. Egalet has raised $70.88 million across 8 funding rounds from investors including Danske Bank, Atlas Venture and Index Ventures. The company has 1 employees as of January 31, 2020. Egalet has completed 1 acquisition, including SPRIX. Egalet offers products and services including Pharmaceutical Products. Egalet operates in a competitive market with competitors including Flexion Therapeutics, Cara Therapeutics, Eliem Therapeutics, Ethypharm and Zogenix, among others.

  • Headquarter Værløse, Denmark
  • Employees 1 as on 31 Jan, 2020
  • Stage Public
  • Sectors
    Healthcare
  • Phone
    Locked
  • Website
    Locked
  • Social
    Locked
  • Legal Name Assertio Holdings, Inc.
Operational Areas
Healthcare → Healthcare Products & Supplies Unlock Sub-Sector Unlock Segment
Healthcare → Healthcare Products & Supplies Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    $2.01 M (USD)
    -78
    as on Dec 31, 2024
  • Net Profit
    -$21.58 M (USD)
    93
    as on Dec 31, 2024
  • EBITDA
    -$24.48 M (USD)
    90
    as on Dec 31, 2024
  • Total Equity Funding
    $70.88 M (USD)

    in 8 rounds

  • Latest Funding Round
    $42.16 M (USD), Post-IPO

    Feb 19, 2019

  • Investors
    Danske Bank

    & 8 more

  • Employee Count
    1

    as on Jan 31, 2020

  • Investments & Acquisitions
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of Egalet

Egalet offers a comprehensive portfolio of products and services, including Pharmaceutical Products.

Product name locked
Category locked
Primary

Develops and distributes prescription drugs for medical treatments

People of Egalet

Headcount 50-200
Employee Profiles 9
Board Members and Advisors 5
Employee Profiles
People
Dan A. Peisert
President, CEO & Director
People
Ajay Patel
SVP & Chief Accounting Officer
People
Paul Schwichtenberg
SVP & Chief Financial Officer
People
Jeff Christensen
SVP, Commercial

Unlock access to complete

Funding Insights of Egalet

Egalet has successfully raised a total of $70.88M across 8 strategic funding rounds. The most recent funding activity was a Post-IPO round of $42.16 million completed in February 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

Investors in Egalet

Egalet has secured backing from 9 investors, including venture fund and institutional investors. Prominent investors backing the company include Danske Bank, Atlas Venture and Index Ventures.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Venture capital investments in technology startups and entrepreneurs.
Locked Locked Locked
Venture capital firm investing in life science and biotechnology sectors
Locked Locked Locked
Investments are made by Sunstone in early-stage European companies.
Locked Locked Locked
Premium access

Investor details for Egalet

Investor domains, locations, round participation, and complete history require an active premium plan.

  • Investor domains
  • Investor locations
  • Funding rounds
  • Participation history

Verified entity values are shown only after access is granted.

Investments & Acquisitions by Egalet

Egalet has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include SPRIX.

Investments
Premium access

Investment portfolio details for Egalet

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Acquisitions
Company Name Description Domain Location Founded Year Amount
Pain relief nasal spray product is featured on SPRIX website.
Locked Locked 2003 Locked
Premium access

Complete acquisition details for Egalet

Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.

  • Transaction dates
  • Acquired stakes
  • Disclosed values
  • Domains and locations

Verified entity values are shown only after access is granted.

Financial Statements - Egalet

Premium access

Detailed financials for Egalet

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Egalet Comparisons

Egalet Primary company
Description
Therapeutics for pain management are developed with abuse-de...
Location
Værløse, Denmark
Founded Year
1995
Annual Revenue
$2.01 M (USD)
Net Profit
-$21.58 M (USD)
EBITDA
-$24.48 M (USD)
Employees
1
As of 2020
Premium access

Peer comparison for Egalet

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of Egalet

Egalet operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Flexion Therapeutics, Cara Therapeutics, Eliem Therapeutics, Ethypharm and Zogenix, among others.

Company Name Domain Founded year HQ Location Description
Locked Locked Locked
Developer of therapies for the treatment of musculoskeletal disorders
Locked Locked Locked
Developer of therapeutics for pain relief and inflammatory diseases
Locked Locked Locked
Develops antibody-based treatments for autoimmune and inflammatory disorders.
Locked Locked Locked
Therapies for pain and addiction treatment are developed.
Locked Locked Locked
Drug delivery systems for CNS disorders and pain are developed.
Locked Locked Locked
Reformulated injectables for chemotherapy side effects and pain are developed.
Premium access

Detailed competitors of Egalet

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Egalet

Premium access

Complete news archive for Egalet

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Egalet

Egalet was founded in 1995 and raised its 1st funding round 11 years after it was founded.

Egalet is headquartered in Værløse, Denmark.

Egalet is a funded company, having raised a total of $70.88M across 8 funding rounds to date.

As of Jan 31, 2020, the latest employee count at Egalet is 1.

Annual revenue of Egalet is $2.01M as on Dec 31, 2024.

Founded in 1995 and based in Vaerlose, Denmark, the company operates in the pharmaceutical sector. Focus is placed on developing therapeutics for pain management, including a pipeline of clinical-stage opioid-based product candidates. These candidates are engineered to resist abuse through physical and chemical manipulation. The underlying technology is applied across various pharmaceutical classes and supports combination products featuring multiple active ingredients with varied release profiles.

Egalet's top competitors include Flexion Therapeutics, Cara Therapeutics and Trevena.

Egalet offers Pharmaceutical Products.

Egalet has made 1 acquisition, including SPRIX.

Egalet has 9 investors. Key investors include Danske Bank, Atlas Venture, Index Ventures, Sunstone, and Omega Funds.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available